This module uses fundamental data of Quoin Pharmaceuticals to approximate its Piotroski F score. Quoin Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Quoin Pharmaceuticals Ltd. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Quoin Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Quoin Pharmaceuticals Altman Z Score, Quoin Pharmaceuticals Correlation, Quoin Pharmaceuticals Valuation, as well as analyze Quoin Pharmaceuticals Alpha and Beta and Quoin Pharmaceuticals Hype Analysis.
Quoin
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Investments
Net Borrowings
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Change To Operating Activities
Total Cash From Financing Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Assets
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Cash
Non Current Assets Total
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Current Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Net Tangible Assets
Current Deferred Revenue
Retained Earnings
Accounts Payable
Non Currrent Assets Other
Non Current Liabilities Total
Other Current Assets
Total Liab
Short Term Debt
Intangible Assets
Common Stock
Net Invested Capital
Net Working Capital
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Net Interest Income
Depreciation And Amortization
Interest Expense
Net Income From Continuing Ops
Cost Of Revenue
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
At this time, Quoin Pharmaceuticals' Net Debt To EBITDA is fairly stable compared to the past year. Debt To Equity is likely to rise to 1,076 in 2024, despite the fact that Net Debt is likely to grow to (2.3 M). At this time, Quoin Pharmaceuticals' Capex To Depreciation is fairly stable compared to the past year. Days Of Inventory On Hand is likely to rise to 0 in 2024, whereas PTB Ratio is likely to drop 0.74 in 2024.
At this time, it appears that Quoin Pharmaceuticals' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Quoin Pharmaceuticals is to make sure Quoin is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Quoin Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Quoin Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Quoin Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Quoin Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
5.97
At this time, Quoin Pharmaceuticals' Book Value Per Share is fairly stable compared to the past year.
Quoin Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Quoin Pharmaceuticals from analyzing Quoin Pharmaceuticals' financial statements. These drivers represent accounts that assess Quoin Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Quoin Pharmaceuticals' important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Quoin Pharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quoin Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quoin Pharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.